Pexacerfont

Pexacerfont

Clinical data
Synonyms	Pexacerfont
Legal status
Legal status	Investigational New Drug
Identifiers
IUPAC name 8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethyl-N- [(1R)-1-methylpropyl]pyrazolo[1,5-a]-1,3,5-triazin-4-amine
CAS Number	459856-18-9
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C18H24N6O
Molar mass	340.4 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pexacerfont (BMS-562086) is a drug developed by Bristol-Myers Squibb which acts as a CRF-1 antagonist.

Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress and drug addiction. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress. Chronic release of CRF and ACTH is believed to be directly or indirectly involved in many of the harmful physiological effects of chronic stress, such as excessive glucocorticoid release, stomach ulcers, anxiety, depression, and development of high blood pressure and consequent cardiovascular problems.

Pexacerfont is a recently developed CRF-1 antagonist which is currently in clinical trials for the treatment of anxiety disorders,[2] and has also been proposed to be useful for the treatment of depression and irritable bowel syndrome.[3]

See Also

• Antalarmin
• Corticotropin releasing hormone antagonists

References

Template:WikiDoc Sources